OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.30

+4.4%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$58.80M
EPS-4.4000
P/E Ratio-0.66
Earnings Date08/11/2026

okur

Research Development Expenses

Last Annual Value

48.26M

3-Year CAGR

23%

5-Year CAGR

25%

10-Year CAGR

12%

OT

OnKure Therapeutics, Inc. Competitors Analysis of research-development-expenses

OKUR · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
48.26M
14.5%11.4%N/A 
30.05M
-8.1%11.4%5.6%
19.03M
-11.8%11.1%-2.6%
33.76M
-26.7%-2.8%16.4%
69.45M
-1.7%-7.8%N/A
18.16M
-6.9%-4.7%-0.6%
56.04M
2.4%1.8%N/A
73.02M
-21.0%-11.2%8.6%
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.3, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.3